恩度单用与恩度联合化疗治疗恶性胸腔积液的临床观察

马恩奇 邹利乐 袁丹

[摘要] 目的 比较恩度单用与恩度联合化疗治疗恶性胸腔积液的疗效。 方法 选取56例恶性胸腔积液患者，随机分为恩度单用组28例，恩度联合化疗组28例，分别进行治疗，评价两组患者的治疗效果、生活质量改善情况及不良反应发生情况。 结果 两组患者均完成1疗程化疗，其中联合组总有效率显著高于单药组，差异有统计学意义（P＜0.05）；两组患者不良反应均轻微，联合组的生活质量改善率明显高于单药组，差异有统计学意义（P＜0.05）。 结论 恩度胸腔灌注化疗治疗恶性胸腔积液是一种安全有效的治疗方法，近期疗效满意，不良反应轻微，其联合顺铂用药疗效较单药更显著，值得进一步研究。

[关键词] 恩度；恶性胸腔积液；化疗

[中图分类号] R734.2???[文献标识码] A???[文章编号] 2095-0616（2012）15-52-02

Clinical observation on the treatment of malignant pleural effusion with endostar and endostar combined with chemotherapy

MA?Enqi??ZOU?Lile??YUAN?Dan

Department of Oncology, the Second Hospital of Zhuzhou City, Zhuzhou 412005,China

[Abstract] Objective To compare the clinical effect of endostar and endostar combined with chemotherapy on the treatment of malignant pleural effusion. Methods Randomly divided 56 cases of malignant pleural effusion to 2 groups: the endostar group and the endostar combined with chemotherapy group(the combined group). And the patients were given treatment separately. The clinical effect, the life quality improvement and the side-effects were observed. Results After 1 course of treatment of endostar combined with chemotherapy, there was significant difference in the clinical effect and in the life quality improvement between the combined group with the endostar group(P＜0.05）. There were slight reactions in the two groups in the side-effects. Conclusion It is a safe and effective way for malignant pleural effusion with the treatment of endostar and chemotherapy and it can receive satisfactory recent effect and low side-effects. It is worth for further research.

[Key words] Endostar; Malignant pleural effusion; Chemotherapy; Clinical observation

肺癌是全球最常见的恶性肿瘤之一，死亡率居所有肿瘤之首。肺癌晚期常常因为肿瘤侵及胸膜而形成恶性胸腔积液。恶性胸腔积液常常反复，治疗困难，预后差，中位生存期短。患者因积液压迫可表现为呼吸困难、胸闷、气促等症状，晚期肿瘤患者的生活质量受到了严重的影响。恩度是一种新型的重组人血管内皮抑制素，研究表明其可以阻断肿瘤细胞的营养来源，抑制肿瘤新生血管的形成，“饿死”肿瘤细胞[1]。近年的研究发现血管内皮抑制素还可以直接作用于肿瘤新生血管内皮细胞，抑制其进一步的增殖分化，可以有效抑制恶性胸、腹腔积液的形成和再发，与化疗药物联合应用具有一定的协同作用。……